Mackenzie Financial’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-8,950
Closed -$354K – 1630
2023
Q2
$354K Buy
8,950
+530
+6% +$18.7K ﹤0.01% 1120
2023
Q1
$205K Buy
+8,420
New +$184K ﹤0.01% 1337
2016
Q4
– Sell
-5,100
Closed -$235K – 746
2016
Q3
$235K Sell
5,100
-24,600
-83% -$1.39M ﹤0.01% 592
2016
Q2
$1.52M Hold
29,700
– – 0.01% 504
2016
Q1
$1.26M Sell
29,700
-1,800
-6% -$91.7K 0.01% 453
2015
Q4
$2.47M Sell
31,500
-18,200
-37% -$1.05M 0.02% 379
2015
Q3
$2.01M Sell
49,700
-3,400
-6% -$180K 0.01% 408
2015
Q2
$2.76M Buy
+53,100
New +$2.64M 0.02% 380

Mackenzie Financial's ISEE Position: Q3 2023 in Review

Mackenzie Financial sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 8,950 shares — an estimated $354K sold.

Mackenzie Financial first reported a position in ISEE in Q2 2015 and held it in 8 quarters. The position peaked at $2.76M in Q2 2015. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.

  • Mackenzie Financial reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Mackenzie Financial sold 8,950 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $354K.
  • Mackenzie Financial first reported a position in IVERIC bio, Inc. Common Stock in Q2 2015 and held it in 8 quarters.
  • Mackenzie Financial's IVERIC bio, Inc. Common Stock position peaked at $2.76M in Q2 2015.
  • 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.

Based on Mackenzie Financial's 13F filing for Q3 2023, filed 25 Oct 2023.